Clinical Trials Directory

Trials / Completed

CompletedNCT03368495

Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines

Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines in Children Under 2 Years Old in Argentina

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
851 (actual)
Sponsor
Alba Maria Ropero · Academic / Other
Sex
All
Age
12 Months – 24 Months
Healthy volunteers
Accepted

Summary

This study evaluates seroconversion against measles, mumps, rubella and yellow fever following vaccination. One-third of children will receive both yellow fever and measles, mumps, and rubella (MMR) vaccines on the same day; one- third of children will receive MMR vaccine at enrollment followed by yellow fever vaccine 4 weeks later; one-third of children will receive yellow fever vaccine at enrollment followed by MMR vaccine 4 weeks later.

Detailed description

The World Health Organization (WHO) and the Pan American Health Organization recommend that yellow fever and measles, mumps and rubella (MMR) vaccines be administered on the same day or at least 4 weeks apart to prevent interference between live vaccines. In 2011 a Brazilian study demonstrated lower seroconversion against yellow fever, rubella, and mumps when the two vaccines were administered on the same day compared with administering them separately. WHO urged that additional studies be conducted to examine this issue. This Phase IV study aims to determine if seroconversion against measles, mumps, rubella, and yellow fever after administration of MMR and yellow fever vaccines on the same day is non-inferior to seroconversion after sequential administration 28 days apart in health 12-month old children.

Conditions

Interventions

TypeNameDescription
BIOLOGICALCo-administration of MMR/YFBoth MMR \& yellow fever vaccines administered on Day 0.
BIOLOGICALMMR followed by YFMMR vaccine administered on Day 0 and yellow fever vaccine administered on Day 28.
BIOLOGICALYF followed by MMRYellow fever vaccine administered on Day 0 and MMR vaccine administered on Day 28.

Timeline

Start date
2015-11-23
Primary completion
2018-06-01
Completion
2018-06-30
First posted
2017-12-11
Last updated
2019-05-21

Locations

4 sites across 1 country: Argentina

Source: ClinicalTrials.gov record NCT03368495. Inclusion in this directory is not an endorsement.